Header links
Intranet
Donate now
image/svg+xml Map
Contact us

21/03/2025

Defensa de Tesi 'ALPHA-Synuclein and Neuromelanin Interplay: unravelling its role in the pathophysiology of Parkinson disease'
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Tesis
14/03/2025

Jornada Dia Mundial de l'Endometriosi
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Jornades

Roadmap

21/02/2025

4th Solidarity Day in Arenys de Munt for Childhood Leukemia
Etiqueta
Iniciativa solidària
19/02/2025

Discover the new VHIR Innovation Process and Innovation HUB launch: driving the future of Healthcare
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Cursos
11/04/2025

Solidarity and charity concert to curb Parkinson's
Etiqueta
Iniciativa solidària
13/03/2025

Per motius aliens se SUSPÈN - Vall d'Hebron Talks by VHIR 'Leveraging the Oxidative Intestinal Microenvironment to Enhance. Intestinotrophic and Anti-Inflammatory Stimuli-Responsive Nanotherapeutics'
Ubicació
Boardroom of the VHIR Edifici Central (Floor 0)
Etiqueta
Vall d'Hebron Talks by VHIR

A phase 2, randomized, placebo-controlled, double-blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb C->t mutation to evaluate the safety, tolerability, phamacokinetics and preliminary efficacy of SLP84

Open
  • Protocol code: SPL84-002
  • EudraCT code: No aplica
  • Research group: Pneumology
  • Service: Pneumology
  • Principal investigator:  Álvarez Fernandez, Antonio
  • Pathology: Malalties del sistema respiratori
  • Phase: Fase II
  • Status: Recruiting volunteers

Estudio fase IIb, aleatorizado, doble ciego, controlado con placeboy con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad deAZD5004 en adultos con diabetes mellitus tipo 2

Open
  • Protocol code: D7261C00001
  • EudraCT code: No aplica
  • Research group: Diabetes and Metabolism
  • Service: Endocrinology
  • Principal investigator:  Ciudin Mihai, Andreea
  • Pathology: Malalties endocrines, nutricionals i metabòliques
  • Phase: Fase II
  • Status: Recruiting volunteers

“Efficacy and safety of co administered cagrilintide and semaglutide(CagriSema) once weekly versus placebo in participants with type 2diabetes and painful diabetic peripheral neuropathy

Open
  • Protocol code: NN9388-7864
  • EudraCT code: No aplica
  • Research group: Diabetes and Metabolism
  • Service: Endocrinology
  • Principal investigator:  Ortiz Zuñiga, Angel Michael
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase II
  • Status: Recruiting volunteers
Subscribe to